PT-141

≥98% HPLCCOA per batchCold-chain shippedIn-house synthesisResearch use only · not for human consumption

Price range: $21.99 through $39.99

Independently verified Tested by IRZC Laboratories Batch NHV26-K8856 · Purity 98.87 % HPLC · Issued 4 Aug 2026 · Cert COA-G4ZZ-JT0P-RVerify at IRZCVerifyScan to verify

An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

FormulaC50H68N14O10
Mol. weight1025.17 g/mol
FormLyophilised powder
0 People watching this product now!
SKU: PEP-030 Category:

Molecular & analytical data

Verified chemistry and third-party reference identifiers for this compound.

Amino acid sequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular formulaC50H68N14O10
Molecular weight1025.17 g/mol
CAS number189691-06-3
PubChem CIDCID 9941379 ↗
Purity standard≥98%
Half-life~2.7 hours (range 1.9-4.0 hours)
BioavailabilitySubcutaneous: ~100%
Origin / sourceSynthetic melanocortin peptide; discovered and developed by Palatin Technologies. AMAG Pharmaceuticals held exclusive North American commercialisation rights under a January 2017 licence and marketed Vyleesi; the licence was mutually terminated in July 2020 and all North American rights returned to Palatin.
Year discoveredFDA approved 2019 (Vyleesi)
PT-141 molecular structure
2D structure · source: PubChem

Reconstitution calculator

Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →

Concentration— mg/mL— mcg per unit
—Draw tounits on a U-100 syringe
—Volume / drawmL
—Complete drawsper vial

—

A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.

Quality & verification

Every batch is characterised before release and ships with documentation.

≥98%HPLC purity
1025.17 g/molMolecular weight
~2.7 hours (range 1.9-4.0 hours)Reported half-life
MS + HPLCIdentity & purity assay
Third-party testedBatches are tested by IRZC Laboratories — independent HPLC + mass-spec confirms identity and purity against that product’s release specification.
Batch-matched COAA certificate of analysis is issued per batch and matched to your vial’s lot number.
Cold-chain fulfilmentLyophilised product is packed with insulated, temperature-controlled shipping.
Controlled synthesisProduced under documented, reproducible in-house processes with lot traceability.

Storage & handling

Keep the peptide stable from delivery through reconstitution.

1
On arrivalStore the sealed, lyophilised vial frozen at −20°C, protected from light and moisture.
2
ReconstitutionAdd bacteriostatic water down the vial wall; swirl gently — do not shake. Use the calculator above to plan volume.
3
After mixingRefrigerate the reconstituted solution at 2–8°C and use within the stability window below.
4
HandlingWork in a clean area, wipe the stopper with alcohol, and avoid repeated freeze–thaw cycles.
Manufacturer storage note

Refrigerate at 2-8°C. Protect from light.

Description

PT-141, marketed as Bremelanotide (Vyleesi), is a synthetic melanocortin receptor agonist that enhances sexual desire through central nervous system pathways rather than vascular mechanisms (unlike PDE5 inhibitors like Viagra). It non-selectively activates melanocortin receptors, particularly MC1R and MC4R, in brain regions involved in sexual arousal. FDA-approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). PT-141 was originally derived from Melanotan II research and represents one of the few approved treatments for female sexual dysfunction.

Certificates of Analysis

Certificates of Analysis

Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.

Batch #IssuedPurityCertificate
NHV26-K8856
COA-G4ZZ-JT0P-R
04 Aug 202698.87 % HPLCVerify at IRZC ↗

“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.

Research & Literature
Reported in research literature — not usage guidance.

The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.

Mechanism of action

Non-selective melanocortin receptor agonist (primarily MC1R and MC4R), activates sexual arousal pathways in CNS, enhances dopaminergic signaling related to desire, does not act on vascular system (non-vasodilatory).

Primary uses / indications

Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved), sexual dysfunction research, libido enhancement

Typical dosage (reported)

1.75 mg subcutaneous injection, at least 45 minutes before anticipated sexual activity. Maximum 1 dose per 24 hours, max 8 doses per month.

Cycle duration (reported)

As-needed basis; not for daily use

Administration route

Subcutaneous injection (auto-injector)

Side effects (reported)

Nausea (most common, ~40%), flushing, injection site reactions, headache, transient hypertension, skin hyperpigmentation with frequent use, fatigue.

Contraindications

Uncontrolled hypertension, known cardiovascular disease. Not approved for men or postmenopausal women. (Orally administered naltrexone-containing products appear in the Vyleesi label as a drug interaction to avoid, not as a contraindication.)

Drug interactions

Contraindicated with naltrexone. Caution with antihypertensives. May cause transient blood pressure elevation.

Reviews (0)
0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “PT-141”

Your email address will not be published. Required fields are marked *

You have to be logged in to be able to add photos to your review.

Specifications

Identity

Full name / brand namesPT-141 (Bremelanotide / Vyleesi)
CategorySexual Health & Hormonal
SubcategoryMelanocortin Agonist
Origin / sourceSynthetic melanocortin peptide; discovered and developed by Palatin Technologies. AMAG Pharmaceuticals held exclusive North American commercialisation rights under a January 2017 licence and marketed Vyleesi; the licence was mutually terminated in July 2020 and all North American rights returned to Palatin.
Year discoveredFDA approved 2019 (Vyleesi)

Chemistry

Amino acid sequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular formulaC50H68N14O10
Molecular weight1025.17 g/mol
CAS number189691-06-3
PubChem CIDCID 9941379 ↗
Purity standard≥98%

Pharmacokinetics

Half-life~2.7 hours (range 1.9-4.0 hours)
BioavailabilitySubcutaneous: ~100%

Regulatory & research status

FDA statusFDA-Approved (2019) as Vyleesi for HSDD in premenopausal women.
Prescription requiredYes — prescription required
Research statusFDA-approved with clinical trial data. Research ongoing for male sexual dysfunction and other melanocortin-mediated conditions.
Clinical trialsNCT02333071 (BMT-301) and NCT02338960 (BMT-302), the two phase III bremelanotide HSDD studies; FDA-approved as Vyleesi (2019)

References

Kingsberg SA et al., "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials", Obstetrics & Gynecology, 2019, DOI: 10.1097/AOG.0000000000003500; Clayton AH et al., "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial", Women's Health, 2016, DOI: 10.2217/whe-2016-0018

Frequently asked questions

What is PT-141?
An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
How does PT-141 work?
Reported in the research literature: Non-selective melanocortin receptor agonist (primarily MC1R and MC4R), activates sexual arousal pathways in CNS, enhances dopaminergic signaling related to desire, does not act on vascular system (non-vasodilatory).
What PT-141 dosage is used in research?
For laboratory research reference only, not usage guidance: 1.75 mg subcutaneous injection, at least 45 minutes before anticipated sexual activity. Maximum 1 dose per 24 hours, max 8 doses per month.
What is the half-life of PT-141?
The reported biological half-life of PT-141 is approximately ~2.7 hours (range 1.9-4.0 hours).
How should PT-141 be stored and reconstituted?
NHOV ships PT-141 as a lyophilised powder. Store unopened vials at −20 °C. Reconstitute with bacteriostatic water; once reconstituted, refrigerate at 2–8 °C, protect from light, and use within the bacteriostatic-water shelf window. Use the NHOV reconstitution calculator to find the exact volume for your target concentration.
What purity is NHOV's PT-141?
NHOV PT-141 is released against a specification of ≥98%, verified by HPLC with mass-spectrometry identity confirmation, and ships with a batch-specific Certificate of Analysis (COA) matched to the vial's lot number.
Is PT-141 approved for human use?
No. PT-141 is sold strictly for laboratory and scientific research use only. It is not for human or veterinary consumption and is not approved as a drug.